Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 20, 2020 16:05 ET | Source: Novan, Inc.

Novan Announces Comprehensive Evaluation of Strategic and Financial Alternatives

Engages H.C. Wainwright & Co. as strategic and financial advisorNITRICIL™ nitric oxide technology platform has enabled multiple early and late-stage pipeline opportunities in dermatology, women’s...
April 03, 2020 08:15 ET | Source: Novan, Inc.

Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement

Per verbal guidance, FDA to consider one additional pivotal trialFDA-generated minutes expected on or before May 1, 2020Sato Pharmaceutical to begin start-up of Phase 1 trial in Japan MORRISVILLE,...
March 26, 2020 16:05 ET | Source: Novan, Inc.

Novan Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

MORRISVILLE, N.C., March 26, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company’s previously announced registered direct...
March 24, 2020 08:10 ET | Source: Novan, Inc.

Novan Announces $8.0 Million Registered Direct Offering Priced At-the-Market

MORRISVILLE, N.C., March 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it has entered into definitive agreements with several institutional...
March 23, 2020 08:15 ET | Source: Novan, Inc.

Novan Announces Data from B-SIMPLE Week 24 Safety Evaluation and COVID-19 Business Updates

Favorable SB206 Week 24 safety and scarring profilesType C teleconference with FDA for SB206 remains scheduled on April 1, 2020Novan intends to screen NVN1000 against a number of viruses, including...
March 03, 2020 16:05 ET | Source: Novan, Inc.

Novan Announces Closing of $5.95 Million Public Offering, including Partial Exercise of the Underwriter’s Option to Purchase Additional Securities

MORRISVILLE, N.C., March 03, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company’s previously announced underwritten public...
February 27, 2020 23:20 ET | Source: Novan, Inc.

Novan Announces Pricing of $5.5 Million Public Offering

MORRISVILLE, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten public...
February 27, 2020 16:01 ET | Source: Novan, Inc.

Novan Announces Proposed Public Offering

MORRISVILLE, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ: NOVN) today announced that it intends to offer and sell a combination of shares of its common...
February 20, 2020 08:15 ET | Source: Novan, Inc.

Novan Receives Phase 2 NIH Federal Grant of Approximately $1.0 Million

Provides funds to evaluate the mechanistic antiviral activity of WH602Novan to progress IND-enabling toxicology and pharmacology studies for WH602 Grant is additive to $223,000 Phase 1 NIH grant...
February 06, 2020 08:30 ET | Source: Novan, Inc.

Novan Provides SB206 Program and Business Update

FDA grants Type C meeting for SB206 to be held on April 1, 2020Last subject completes last visit, Week 24 safety evaluationAdditional 12-week efficacy and safety data provided MORRISVILLE, N.C., Feb....

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right